Resumen
Las enfermedades de nervio periférico son relativamente frecuentes en los pacientes críticos. Dichas condiciones se pueden dividir en aquellas que llevan al ingreso a la UCI (primarias) o las que resultan de otras enfermedades sistémicas de base (secundarias). El síndrome de Guillain-Barré-Landry es la entidad primaria más común. La polineuromiopatía de cuidado crítico es tal vez la entidad secundaria de mayor incidencia. Es esta revisión se incluyen estas enfermedades y también la porfiria intermitente aguda. Si presentan los rasgos más sobresalientes de dichos síndromes, sus etiologías, y tratamientos.
Citas
Ropper A, Wijdicks E, Truaux B. Guillain-Barre Syndrome. Philadelphia: FA Davis; 1991.
Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology 1985;35:1096-104.
Schonberger LB, Hurwitz ES, Katona P, Holman RC, Bregman DJ. Guillain-Barre syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol 1981;9:S31-8.
Larsen JP, Kvale G, Nyland H. Epidemiology of the Guillain-Barre syndrome in the county of Hordaland, Western Norway. Acta Neurol Scand 1985;71:43-7.
Alter M. The epidemiology of Guillain-Barre syndrome. Ann Neurol 1990;27:S7-12.
Dowling PC, Menonna JP, Cook SD. Guillain-Barre syndrome in Greater New York-New Jersey. Jama 1977;238:317-8.
Baoxun Z, Yinchang Y, Huifen H, Xiuqin L. Acute polyradiculitis (Guillain-Barre syndrome): an epidemiological study of 156 cases observed in Beijing. Ann Neurol 1981;9:S146-8.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27:S21-4
Kappas A. The porphyrias. In: Scriver C, ed. The metabolic basis of inherited disease. New York: McGraw- Hill, 1989: 1305-1365.
Torbey MT, Suarez JI, Geocadin R. Less common causes of quadraparesis and respiratory failure. In: Suarez JI ed. Neurology and Neurosurgical Critical Care. Totowa, NJ: The Humana Press; 2004:493-514
Sagar S. Toxic and metabolic Disorders. In: Samuels M, ed. Manual of neurologic therapeutics, 5th Ed. Boston: Little, Brown and co, 2005: 299-301.
Bolton CF. Critical illness polyneuropathy and myopahty. Crit Care Med 2001;29:2388-2390
de Letter MAC, Schmitz PIM, Visser LH, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001;29:2281-2286.
Hund EF, Fogel W, Krieger D, DeGeorgia M, Hacke
W. Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure. Crit Care Med 1996;24:1328-1333
Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet 1996;347:1579-1582
Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996;24:1408-1416
Schwarz J, Planck J, Briegel J, Straube A. Single-fiber electromyography, nerve conduction studies, and conventional electromyography in patients with critical- illness polyneuropathy: evidence for alesion of terminal motor axons. Muscle Nerve 1997;20:696-701
Hund E. Myopathy in critically ill patients. Crit Care Med 1999;27:2544-2547
Hund E. Critical illness polyneuropathy. Curr Opin Neurol 2001;14:649-653
Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 2001;248:929-934
Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and Gram- negative sepsis. Intensive Care Med 1997;23:1144-1149
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.